The FDA's fast track designation will facilitate rapid development and expedited review of Biogen's Alzheimer's disease ...

Roche has reported preliminary results on its Alzheimer’s disease prospect trontinemab. | Roche has reported preliminary ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

A new drug developed to slow the progression of Alzheimer’s disease has been turned down for approval by the European drugs ...

Delve into how the biotech industry is pivoting from the amyloid hypothesis to find new Alzheimer's disease treatments.